Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer

Multigenerational maternal obesity increases the incidence of HCC in offspring via miR-27a-3p

(2020) Yu Sun et al.   JOURNAL OF HEPATOLOGY

Targeting mitosis exit: A brake for cancer cell proliferation

(2019) Xinran Liu et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer

(2019) Sofia Genta et al.   Current Oncology Reports

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer

(2019) Qiming Wang et al.   Journal of Hematology & Oncology

Histone methyltransferase G9a protects against acute liver injury through GSTP1

(2019) Yu Zhang et al.   CELL DEATH AND DIFFERENTIATION

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

(2018) D Westover et al.   ANNALS OF ONCOLOGY

Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function

(2018) Lixin Wan et al.   MOLECULAR CELL

Reducing protein regulator of cytokinesis 1 as a prospective therapy for hepatocellular carcinoma

(2018) Xinran Liu et al.   Cell Death & Disease

Lung Cancer Therapy Targeting Histone Methylation: Opportunities and Challenges

(2018) Yuchen Chen et al.   Computational and Structural Biotechnology Journal

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors

(2018) Xun Huang et al.   CELL

Emerging EZH2 Inhibitors and Their Application in Lymphoma

(2018) Jennifer K. Lue et al.   Current Hematologic Malignancy Reports

Histone demethylase UTX is a therapeutic target for diabetic kidney disease

(2018) Hong Chen et al.   JOURNAL OF PHYSIOLOGY-LONDON

Glyceraldehyde-3-phosphate dehydrogenase promotes liver tumorigenesis by modulating phosphoglycerate dehydrogenase

(2017) Shanshan Liu et al.   HEPATOLOGY

ELABELA and an ELABELA Fragment Protect against AKI

(2017) Hong Chen et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

METCopy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis ofEGFR-mutant Lung Cancer

(2017) Shigeki Nanjo et al.   MOLECULAR CANCER THERAPEUTICS

MacroH2A1.1 cooperates with EZH2 to promote adipogenesis by regulating Wnt signaling

(2017) Danyang Wan et al.   Journal of Molecular Cell Biology

ANGPTL8 negatively regulates NF-κB activation by facilitating selective autophagic degradation of IKKγ

(2017) Yu Zhang et al.   Nature Communications

EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics

(2017) Itaru Yamamoto et al.   Oncotarget

Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance

(2017) Heinz Hammerlindl et al.   Journal of Cell Communication and Signaling

Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer

(2016) Li Zhang et al.   CHINESE MEDICAL JOURNAL

Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia

(2016) Stefanie Göllner et al.   NATURE MEDICINE

Targeting EZH2 in cancer

(2016) Kimberly H Kim et al.   NATURE MEDICINE

The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer

(2015) Muyang Ding et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations

(2015) Chao-Hua Chiu et al.   Journal of Thoracic Oncology

Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression

(2015) Nienke A. de Vries et al.   Cell Reports

Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer

(2014) Claudia Fumarola et al.   BIOCHEMICAL PHARMACOLOGY

MPHOSPH1: A Potential Therapeutic Target for Hepatocellular Carcinoma

(2014) X. Liu et al.   CANCER RESEARCH

VEGF/VEGFR-2 Upregulates EZH2 Expression in Lung Adenocarcinoma Cells and EZH2 Depletion Enhances the Response to Platinum-Based and VEGFR-2-Targeted Therapy

(2014) E. Riquelme et al.   CLINICAL CANCER RESEARCH

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

(2013) Yuankai Shi et al.   LANCET ONCOLOGY

The quest to overcome resistance to EGFR-targeted therapies in cancer

(2013) Curtis R Chong et al.   NATURE MEDICINE

Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation—diversity, ductility, and destiny

(2012) Kenichi Suda et al.   CANCER AND METASTASIS REVIEWS

MYC Acts via the PTEN Tumor Suppressor to Elicit Autoregulation and Genome-Wide Gene Repression by Activation of the Ezh2 Methyltransferase

(2012) M. Kaur et al.   CANCER RESEARCH

Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses lung cancer growth by targeting Aurora B

(2012) Xiang Li et al.   CARCINOGENESIS

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

(2012) Zhenfeng Zhang et al.   NATURE GENETICS

EZH2 mutational status predicts poor survival in myelofibrosis

(2011) P. Guglielmelli et al.   BLOOD

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

(2010) Alexa B. Turke et al.   CANCER CELL

Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells

(2009) S. Benavente et al.   CLINICAL CANCER RESEARCH

Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

(2009) David Jackman et al.   JOURNAL OF CLINICAL ONCOLOGY